Novo Nordisk signs up to €1.165 billion Nanexa drug-delivery deal on September 25, 2026 Diabetes Mellitus, Non-Insulin-Dependent Drug Delivery Systems Glucagon-Like Peptide 1 long-acting injectables Nanexa Novo Nordisk Obesity PharmaShell +